Jiangsu Hengrui Pharmaceuticals: The HRS-6213 injection has received a notification of approval for clinical drug trials.

Breakings · 08:55

Jiangsu Hengrui Pharmaceuticals announced that its subsidiary, Tianjin Hengrui Pharmaceuticals Co., Ltd., has received a notification of approval for the HRS-6213 injection issued by the National Medical Products Administration, and clinical trials will start soon. The HRS-6213 injection is a tumor protein-bound injection used for diagnosing and evaluating solid tumors via PET imaging.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Recommended

Died at the age of 97! Lee Shau Kee, the founder of Henderson Land Development, passed away, recalling the legendary life of…

Huashang Strategy · Mar 17, 2025 15:10
Tencent, Meituan, and PDD Holdings all release their Earnings Reports this week, and the market is closely watching these nu…

wallstreetcn · Mar 17, 2025 13:13
U.S. stock market in the early session | The three major indices opened lower and then rose, China Concept Stocks and Quantu…

Sina Finance · Mar 17, 2025 14:17
The American version of "Huabei" Affirm fell nearly 15%, with reports that Swedish fintech company Klarna will replace it as…

Zhitong Finance · Mar 17, 2025 14:16
Stimulated by DeepSeek, this year Global Technology giants' AI spending may reach 370 billion dollars, exceeding 520 billion b…

wallstreetcn · Mar 17, 2025 14:38

Write a comment

恒瑞医药：HRS-6213注射液获药物临床试验批准通知书

Jiangsu Hengrui Pharmaceuticals: The HRS-6213 injection has received a notification of approval for clinical drug trials.

Risk Disclaimer

Statement